Dipexium

Locilex cream

A First of its Kind

Currently in late stage clinical development, Locilex® (pexiganan cream 0.8%) could become the first antibiotic FDA approved specifically for mild infections of diabetic foot ulcers.

Learn more about Locilex®
About Dipexium

About Dipexium

Dipexium Pharmaceuticals is a late stage pharmaceutical company focused on the development and commercialization of Locilex®, a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate skin and skin structure infections.

Learn more about Dipexium Pharmaceuticals
Therapeutic Areas

Therapeutic Areas

Locilex® has demonstrated potent, bactericidal activity against gram-positive, gram-negative, aerobic, anerobic, and resistant bacteria. We believe this broad spectrum of activity, coupled with an excellent safety profile, and lack of systemic absorption, could allow Locilex® to become an important front-line treatment option across many mild and moderate skin and skin structure infections.

Learn more about our Therapeutic Areas

Investor Presentation

Investor Presentation

View our
Investor Presentation

Download PDF
Go to Investor Relations

Stock Info

NASDAQ
DPRX
Mkt Cap
Volume
Change
View Detailed Stock Info
Sign up for Email Alerts Be the first to receive breaking news.